- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Transcript
How do you think payers are going to manage having so many adalimumab biosimilars to choose from?
Casberg: That's what we do as a company: we help people make formulary and drug management decisions. So, I see there's 3 options. As a payer, you can stay with AbbVie’s [product] all the way, which avoids member disruption and makes things more smooth but you don't get biosimilar adoption. And from an optics perspective, I think adoption of biosimilars is becoming more required these days.
So, one option is AbbVie, all in. You may not get quite as much savings as going with biosimilars, but you also now don’t have some of the hurdles and hassles you get with going with biosimilars.
Number 2 is going middle of the road. Keep Humira [reference adalimumab] on formulary, but also add some biosimilars at parity. So, have both options available. It allows you to maintain some Humira rebate and also allows you to take advantage of some biosimilars savings. So that's option 2, kind of meeting halfway.
And then the last one is biosimilars, all in. Take [Humira] off formulary and go all in with biosimilars. Try to convert as much of the market share as you can.
So, those are the strategies, and as far as all those different options you probably add the [originator], and/or 1 or 2 of the biosimilars, and then see how the cards fall.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
